Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $215.88 Average PT from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $215.88.

Several brokerages have weighed in on ALNY. Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research note on Friday, February 16th. HC Wainwright reaffirmed a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. Citigroup decreased their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 13th.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd increased its stake in Alnylam Pharmaceuticals by 69.1% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after purchasing an additional 77,307 shares in the last quarter. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after purchasing an additional 30,608 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Alnylam Pharmaceuticals by 630.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after purchasing an additional 22,580 shares in the last quarter. Asset Management One Co. Ltd. increased its stake in Alnylam Pharmaceuticals by 41.3% in the fourth quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock valued at $13,569,000 after purchasing an additional 20,268 shares in the last quarter. Finally, Royal London Asset Management Ltd. increased its stake in Alnylam Pharmaceuticals by 86.7% in the third quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock valued at $54,303,000 after purchasing an additional 142,357 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.2 %

NASDAQ ALNY opened at $150.31 on Tuesday. The stock has a market cap of $18.93 billion, a P/E ratio of -42.47 and a beta of 0.41. The company’s 50-day simple moving average is $150.01 and its 200 day simple moving average is $165.35. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.68) EPS. Research analysts anticipate that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.